{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-squamous%2C+Non-Small-Cell+Lung+Cancer", "query": { "condition": "Non-squamous, Non-Small-Cell Lung Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 741, "total_pages": 75, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-squamous%2C+Non-Small-Cell+Lung+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T14:02:37.609Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05014815", "title": "Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)", "Nonsmall Cell Lung Cancer, Stage IIIB", "Nonsmall Cell Lung Cancer, Stage IV" ], "interventions": [ { "name": "Ociperlimab", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 272, "start_date": "2021-11-16", "completion_date": "2024-09-04", "has_results": true, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-06-10T14:02:37.609Z", "location_count": 11, "location_summary": "Los Angeles, California • Iowa City, Iowa • Las Vegas, Nevada + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05014815" }, { "nct_id": "NCT00002624", "title": "Video-Assisted Surgery Followed by Radiation Therapy in Treating Patients With Stage I Non-small Cell Lung Cancer and Poor Heart and Lung Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "diagnostic thoracoscopy", "type": "PROCEDURE" }, { "name": "therapeutic thoracoscopy", "type": "PROCEDURE" }, { "name": "video-assisted surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "1994-12", "completion_date": "2005-08", "has_results": false, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-06-10T14:02:37.609Z", "location_count": 13, "location_summary": "Denver, Colorado • Des Moines, Iowa • Boston, Massachusetts + 8 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002624" }, { "nct_id": "NCT02133196", "title": "T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Non-Small Cell Lung Cancer", "Squamous Cell Carcinoma", "Advanced NSCLC", "Adenosquamous Carcinoma", "Adenocarcinoma" ], "interventions": [ { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Young TIL", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 85, "start_date": "2014-10-23", "completion_date": "2027-10-23", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-06-10T14:02:37.609Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02133196" }, { "nct_id": "NCT05799274", "title": "Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers", "Pancreatic Ductal Adenocarcinoma", "Non-small Cell Lung Cancer (NSCLC)", "Esophageal Squamous Cell Carcinoma", "Cervical Cancer", "Endometrial Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "RAD301 ([68Ga]-RAD301)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Radiopharm Theranostics, Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2023-11-09", "completion_date": "2026-05", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-06-10T14:02:37.609Z", "location_count": 2, "location_summary": "Princeton, New Jersey • The Bronx, New York", "locations": [ { "city": "Princeton", "state": "New Jersey" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05799274" }, { "nct_id": "NCT03517488", "title": "A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Breast Carcinoma", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Non-small Cell Lung Carcinoma", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Endometrial Carcinoma", "Mesothelioma", "Neuroendocrine Carcinoma", "Cervical Cancer", "Small Cell Lung Carcinoma", "Squamous Cell Carcinoma of the Anus", "Castration-Resistant Prostate Carcinoma", "Nasopharyngeal Carcinoma", "Cholangiocarcinoma", "Basal Cell Carcinoma", "Ovarian Carcinoma", "Fallopian Tube Carcinoma", "Thymoma", "Thymic Carcinoma", "Squamous Cell Carcinoma of the Penis", "Vulvar Carcinoma", "Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy", "Malignant Adnexal Neoplasms", "Non-squamous Cell Salivary Gland Carcinoma" ], "interventions": [ { "name": "XmAb20717", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2018-07-10", "completion_date": "2022-09-06", "has_results": false, "last_update_posted_date": "2022-12-01", "last_synced_at": "2026-06-10T14:02:37.609Z", "location_count": 17, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03517488" }, { "nct_id": "NCT05267626", "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Cancer", "Cutaneous Melanoma", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "AU-007", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aulos Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2022-04-04", "completion_date": "2026-06-12", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-06-10T14:02:37.609Z", "location_count": 11, "location_summary": "Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 8 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05267626" }, { "nct_id": "NCT02193282", "title": "Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Non-Squamous Non-Small Cell Carcinoma", "Stage IB Lung Non-Small Cell Carcinoma AJCC v7", "Stage II Lung Non-Small Cell Cancer AJCC v7", "Stage IIA Lung Non-Small Cell Carcinoma AJCC v7", "Stage IIB Lung Non-Small Cell Carcinoma AJCC v7", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Clinical Observation", "type": "OTHER" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Placebo Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 390, "start_date": "2015-02-11", "completion_date": "2027-02-03", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-06-10T14:02:37.609Z", "location_count": 1404, "location_summary": "Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 888 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02193282" }, { "nct_id": "NCT05317078", "title": "A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-squamous Non-small Cell Lung Cancer", "Epithelial Ovarian Cancer", "Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors" ], "interventions": [ { "name": "AMG 794", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2023-02-28", "completion_date": "2024-04-01", "has_results": false, "last_update_posted_date": "2025-10-08", "last_synced_at": "2026-06-10T14:02:37.609Z", "location_count": 4, "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05317078" }, { "nct_id": "NCT04524689", "title": "Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)" ], "interventions": [ { "name": "SAR408701 (Tusamitamab ravtansine)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2020-10-26", "completion_date": "2024-12-24", "has_results": true, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-06-10T14:02:37.609Z", "location_count": 1, "location_summary": "Westwood, Kansas", "locations": [ { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04524689" }, { "nct_id": "NCT01391143", "title": "Safety Study of MGA271 in Refractory Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer", "Melanoma", "Renal Cell Carcinoma", "Triple-negative Breast Cancer", "Head and Neck Cancer", "Bladder Cancer", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "MGA271", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 179, "start_date": "2011-07", "completion_date": "2019-04-18", "has_results": false, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-06-10T14:02:37.609Z", "location_count": 12, "location_summary": "Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01391143" } ] }